How do we determine whether Ascendis Pharma A/S (NASDAQ:ASND) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that their consensus long positions have historically outperformed the market when we adjust for known risk factors.

Ascendis Pharma A/S (NASDAQ:ASND) shareholders have witnessed a decrease in hedge fund sentiment of late. ASND was in 33 hedge funds' portfolios at the end of the second quarter of 2019. There were 35 hedge funds in our database with ASND holdings at the end of the previous quarter. Our calculations also showed that ASND isn't among the 30 most popular stocks among hedge funds.

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey's flagship best performing hedge funds strategy returned 25.8% year to date (through May 30th) and outperformed the market even though it draws its stock picks among small-cap stocks. This strategy also outperformed the market by 40 percentage points since its inception (see the details here). That's why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.

Unlike some fund managers who are betting on Dow reaching 40000 in a year, our long-short investment strategy doesn't rely on bull markets to deliver double digit returns. We only rely on hedge fund buy/sell signals. Let's analyze the fresh hedge fund action regarding Ascendis Pharma A/S (NASDAQ:ASND).

What have hedge funds been doing with Ascendis Pharma A/S (NASDAQ:ASND)?

At Q2's end, a total of 33 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -6% from the first quarter of 2019. Below, you can check out the change in hedge fund sentiment towards ASND over the last 16 quarters. With the smart money's positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were increasing their stakes substantially (or already accumulated large positions).

More specifically, RA Capital Management was the largest shareholder of Ascendis Pharma A/S (NASDAQ:ASND), with a stake worth $475.9 million reported as of the end of March. Trailing RA Capital Management was OrbiMed Advisors, which amassed a stake valued at $442.9 million. Baker Bros. Advisors, Vivo Capital, and venBio Select Advisor were also very fond of the stock, giving the stock large weights in their portfolios.